发明授权
US08183248B2 Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors
失效
取代的吡咯并[2,3-d]嘧啶和组合物作为蛋白激酶抑制剂
![Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors](/docs/US/2012-05-22/US08183248B2/abs.jpg.600x600.jpg)
- 专利标题： Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors
- 专利标题（中）： 取代的吡咯并[2,3-d]嘧啶和组合物作为蛋白激酶抑制剂
-
申请号： US11914308申请日： 2006-05-10
-
公开(公告)号： US08183248B2公开(公告)日： 2012-05-22
- 发明人: Advait Nagle , Nathanael Schiander Gray , Yi Liu , Pingda Ren , Taebo Sim , Shuli You
- 申请人： Advait Nagle , Nathanael Schiander Gray , Yi Liu , Pingda Ren , Taebo Sim , Shuli You
- 申请人地址： BM Hamilton
- 专利权人： IRM LLC
- 当前专利权人： IRM LLC
- 当前专利权人地址： BM Hamilton
- 代理机构： Genomics Institute of the Novartis Research Foundation
- 代理商 Chihang Amy Smith
- 国际申请： PCT/US2006/018096 WO 20060510
- 国际公布： WO2006/124462 WO 20061123
- 主分类号： C07D487/04
- IPC分类号： C07D487/04 ; A61K31/519
![Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors](/abs-image/US/2012/05/22/US08183248B2/abs.jpg.150x150.jpg)
摘要：
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Abl, Bcr-Abl, Bmx, BTK, b-RAF, c RAF, CSK, cSRC, Fes, FGFR3, Flt3, IKKα, IKKβ, JNK1α1, JNK2α2, Lck, Met, MKK4, MKK6, p70S6K, PAK2, PDGFRα, PKA, PKCα, PKD2, ROCK-II, Ros, Rsk1, SAPK2α, SAPK2β, SAPK3, SAPK4, SGK, Syk, Tie2 and TrkB kinases.
公开/授权文献
- US20090118273A1 Compounds and Compositions as Protein Kinase Inhibitors 公开/授权日：2009-05-07
信息查询
